On June 18th, 2022, RainMed's Satellite Symposium at CIT (China Interventional Therapeutics Congress) was successfully held. Renowned cardiovascular experts from all over China had a heated discussion on caFFR and caIMR’s research progress, clinical significance and application scenarios. The Satellite Symposium provided new solutions for clinical diagnosis and treatment of coronary heart disease.

At present, there is no clinical quantitative measurement product that can easily and effectively diagnose coronary microcirculation. The large-scale clinical application of caIMR--the global pioneering technology--will surely bring epoch-making significance to precise diagnosis and treatment in cardiovascular field, and provide diagnostic basis and research direction for the development of microcirculation drugs and devices. To conclude, why is caIMR so promising? We can refer to the following five reasons.

Firstly, research shows that caIMR has high accuracy, sensitivity and specificity.

caIMR is a microcirculation evaluation system suitable for surgery in cath lab. It is highly repetitive and is not affected by factors such as blood pressure, heart rate, age and sex. It can correctly diagnose real patients as positive and people without disease as negative. Research shows that the accuracy of online and offline measurement was as high as 93.81% and 94.69% respectively. caIMR has an amazing accuracy.

Secondly, caIMR requires no pressure guidewire, hyperemic agents and SPSS injection

caIMR is easy to use. Microcirculatory dysfunction is an important cause of myocardial ischemia. Traditional guidewire-based IMR detection technology requires pressure guide wire, hyperemic agents, and repeated injections of SPSS. Since the operation is complex and risky, it is mostly used in scientific research rather than daily application. By comparison, caIMR requires no pressure guidewire, hyperemic agents and SPSS injection, and it only takes 2-3 minutes to measure IMR noninvasively.

Thirdly, caIMR can reduce diagnostic time from 40-60 minutes to an average of less than 5 minutes

caIMR is safe and fast. Because of specially optimized CFD algorithm, IMR can be measured in real time during surgery without changing surgeons' surgery habits. It can reduce diagnostic time from 40-60 minutes to an average of less than 5 minutes. It can also significantly reduce the intraoperative risks arising from invasive measurements, help the surgeons make better treatment plan, reduce the waste of surgical resources, and improve surgical efficiency.

Fourthly, caIMR can also be used for prognosis.

caIMR can predict the clinical outcome in the patients with MINOCA, and in the SCAD/ STEM patients after PCI. For patients with STEMI after PCI, caIMR is better in recognizing microvascular occlusion than TIMI flow grade and myocardial imaging density grade, and it is also better than CMR in terms of availability and cost.

Fifthly, a combination of caFFR and caIMR can provide a comprehensive evaluation of blood vessels.

caIMR is also able to work together with another revolutionary functional coronary angiography tool caFFR for the assessment of epicardial stenosis, which provides a complete functional evaluation from the epicardial coronary artery to intramycardial microcirculation.

Statistically, up to 70% patients evaluated by coronary angiography have microcirculatory dysfunction. The growing clinical demand reveals the huge market space for IMR. RainMed’s caIMR overcomes the limitations of traditional guide wire-based IMR, and will become the world's first innovative IMR product approved for marketization to meet the blue ocean market of more than 10 billion yuan.